Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Pharmacotherapeutic group: decongestants for topical use, sympathomimetics, plain.
ATC Code: R01AA07
Otrivine Adult Menthol Nasal Spray is a sympathomimetic agent with marked alpha-adrenergic activity, and is intended for use in the nose. It constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. It also reduces associated symptoms of mucus hypersecretion and facilitates drainage of blocked secretions. This enables patients suffering from colds to breathe more easily through the nose.
The effect of Otrivine Adult Menthol Nasal Spray begins within a few minutes and lasts for up to 10 hours.
Otrivine is generally well tolerated and does not impair the function of ciliated epithelium.
Otrivine Adult Menthol Nasal Spray also contains cooling aromatic vapours of menthol and eucalyptol.
Plasma concentrations of xylometazoline in man after local nasal application of the product are very low and close to the limit of detection.
Systemic absorption may occur following nasal application of xylometazoline hydrochloride solutions. It is not used systemically.
Xylometazoline has no mutagenic effect. No teratogenic effects were shown in a study where xylometazoline was given subcutaneously in mice and rats.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
